Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities. The deal also includes additional ...

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

A UK company developing technology spun out of the University of Queensland is poised for growth after being acquired by ...

Sanofi’s $1.76 billion acquisition of Vicebio has delivers a windfall for the University of Queensland — and highlighted a ...

The University of Queensland (UQ) is hailing the acquisition of biotech company Vicebio by French pharma giant Sanofi for up ...

Health care companies recouped some of their recent losses amid generally strong earnings and deal activity. British drug maker AstraZeneca said it plans to invest $50 billion in the U.S. by 2030, ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion ...

George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of ...

Astra, led by boss Pascal Soriot (pictured), said it is accelerating its expansion in US with an investment that will create ...

General Motors' net income shrank 35% in the second quarter despite strong sales gains. The tech entrepreneur's estate might be wiped out after a U.K. court ruled it owed Hewlett Packard Enterprise ...

“Vicebio’s Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine ...

Sanofi is acquiring UK biotechnology company Vicebio for up to US$1.6 billion ($2.4 billion) in the largest deal involving a ...